
Sign up to save your podcasts
Or
Today I dive into the emerging therapies for psoriatic arthritis, focusing on the IL17i ixekizumab and the recently published SPIRIT-H2H trial. It's a great combination of my favorite thing in RCTs (head to head trials) and my least favorite thing in RCTs (RCTs that were designed in such a way that they don't answer the question I want to know).
4.9
111111 ratings
Today I dive into the emerging therapies for psoriatic arthritis, focusing on the IL17i ixekizumab and the recently published SPIRIT-H2H trial. It's a great combination of my favorite thing in RCTs (head to head trials) and my least favorite thing in RCTs (RCTs that were designed in such a way that they don't answer the question I want to know).
496 Listeners
118 Listeners
3,321 Listeners
1,081 Listeners
119 Listeners
514 Listeners
67 Listeners
5 Listeners
171 Listeners
11 Listeners
0 Listeners
1 Listeners
0 Listeners
5 Listeners
18 Listeners